A new target for control of obesity

November 08, 2004

La Jolla, CA. A team of researchers led by The Burnham Institute's Gen-Sheng Feng, Ph.D. has discovered that a protein called Shp2 plays a critical role in obesity. Published on November 9th in Proceedings of the National Academy of Sciences, these results show that Shp2 has potential of becoming a novel pharmaceutical target for treatment of individuals suffering obesity and leptin resistance.

In 2003, the World Health Organization identified obesity as a growing global threat affecting more than 300 million people worldwide. Although it is commonly believed that obese individuals can overcome their condition by simply eating less and exercising more, compelling scientific data suggest that the heritability of obesity is greater than breast cancer, heart disease, or schizophrenia. Morbid obesity is considered as the disease of the twenty-first century, with the affected individuals at higher risk for diabetes, heart disease, hypertension and cancer, collectively known as metabolic syndrome.

Shp2, a Src homology 2-containing tyrosine phosphatase, was discovered by Dr. Feng and others over a decade ago. It is present in each cell type in the body and is implicated in a variety of growth factor or cytokine pathways present in these cells.

The physiological function of Shp2 is largely unknown. Whether it is active in multiple pathways or focused on a single pathway remains to be seen. In recent years, in vitro experiments suggest that Shp2 plays a role in regulating the protein leptin. Leptin, produced in fat cells, is a hormone that regulates body weight, metabolism, and reproduction. The primary action site for leptin is within the hypothalamus, located in the forebrain.

Dr. Feng and his colleagues took the investigation to the next level by looking at the role of Shp-2 in live mice. They bred a special kind of mouse in which the elimination of Shp-2 was confined to the mouse's forebrain by using a highly advanced genetic engineering technique called "cell-type specific gene knockout". The progeny were mice with early-onset obesity that had increased levels of leptin, insulin, glucose, and triglycerides. Furthermore, the mice could gain weight by eating normal amounts of food, which supports a role for Shp-2 in metabolism.

"Shp-2 has different functions in each cell," says Dr. Feng. "We found that in adult neuoronal cells, it's important function is to control metabolism. This hypothesis will be tested further, but it appears to present a target for the design of new anti-obesity drugs that could help individuals suffering from obesity by increasing their sensitivity to leptin."

Dr. Feng is an Associate Professor in the Burnham Institute's Program on Signal Transduction.
This work was supported by grants from the National Institutes of Health. Dr. Feng acknowledges with appreciation the American Diabetes Foundation, which supported the research that led to his discovery of the Shp2 tyrosine phosphatase early in his career.

The Burnham Institute is an independent, nonprofit, public benefit organization dedicated to biomedical research. The Institute employs over 625 persons and is home to three research centers, including a Cancer Center sponsored by the National Cancer Institute, the Del E. Webb Center for Neuroscience and Aging, which focuses on diseases such as stroke, Alzheimer's, Parkinson's, and other neurodegenerative diseases, and the recently established Infectious and Inflammatory Disease Center. The Institute operates on an annual budget of over $68 Million. These funds are derived primarily from federal grants. Other important sources of funding include private foundations, philanthropy, and technology transfer. To learn more about The Burnham Institute, visit our website at www.burnham.org.

Sanford-Burnham Prebys Medical Discovery Institute

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.